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Abstract
Background: Urinary tract infections [UTIs] are very common in people with Spinal Cord Injury [SCI]. UTIs are
increasingly difficult and expensive to treat as the organisms that cause them become more antibiotic resistant.
Among the SCI population, there is a high rate of multi-resistant organism [MRO] colonisation. Non-antibiotic
prevention strategies are needed to prevent UTI without increasing resistance. Probiotics have been reported to be
beneficial in preventing UTIs in post-menopausal women in several in vivo and in vitro studies. The main aim of this
study is to determine whether probiotic therapy with combinations of Lactobacillus reuteri RC-14 + Lactobacillus
rhamnosus GR-1 [RC14-GR1] and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 [LGG-BB12] are effective in
preventing UTI in people with SCI compared to placebo.
Method: This is a multi-site randomised double-blind double-dummy placebo-controlled factorial design study
conducted in New South Wales, Australia. All participants have a neurogenic bladder as a result of spinal injury.
Recruitment started in April 2011.
Participants are randomised to one of four arms, designed for factorial analysis of LGG-BB12 and/or RC14-GR1 v Placebo.
This involves 24 weeks of daily oral treatment with RC14-GR1 + LGG-BB12, RC14-GR1 + placebo, LGG-BB12 + placebo or
two placebo capsules. Randomisation is stratified by bladder management type and inpatient status. Participants are
assessed at baseline, three months and six months for Short Form Health Survey [SF-36], microbiological swabs of rectum,
nose and groin; urine culture and urinary catheters for subjects with indwelling catheters. A bowel questionnaire is
administered at baseline and three months to assess effect of probiotics on bowel function.
The primary outcome is time from randomisation to occurrence of symptomatic UTI. The secondary outcomes are
change of MRO status and bowel function, quality of life and cost-effectiveness of probiotics in persons with SCI. The
primary outcome will be analysed using survival analysis of factorial groups, with Cox regression modelling to test the
effect of each treatment while allowing for the other, assuming no interaction effect. Hazard ratios and Kaplan-Meier
survival curves will be used to summarise results.
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Discussion: If these probiotics are shown to be effective in preventing UTI and MRO colonisation, they would be a very
attractive alternative for UTI prophylaxis and for combating the increasing rate of antibiotic resistance after SCI.
Trial registration: Australian New Zealand Clinical Trials Registry [ACTRN 12610000512022]. Date of registration:
21 June 2010.
Keywords: Urinary prophylaxis, Multi-resistant organisms, Antibiotic resistance, Probiotics, Biofilm, Microbial
community profiles
Background
Urinary tract infections [UTIs] are very common in
people with a neurogenic bladder. People with a spinal
cord injury [SCI] and people with the spinal demyelinating
form of Multiple Sclerosis [MS] are highly susceptible to
the development of neurogenic bladder dysfunction.
UTIs have a high societal cost and current prevention
strategies do not work. People with neurogenic bladder
are at significant risk from UTI with approximately two
[2] UTI episodes per year on average for persons with
SCI [1]. One of the major clinical challenges for SCI
patients and clinicians is that when patients get a UTI,
simple oral antibiotics frequently are ineffective due
to the high numbers of multi-resistant-organism [s]
[MROs] within SCI populations [about 40–50 % of
SCI people] [1, 2]. This greatly amplifies the health,
societal and economic consequences of disease and
can even lead to life threatening clinical problems
that can spread if not controlled through hospitals
and the community. Health care costs associated with
cross infection are estimated at US$18–30 billion
yearly in the USA and UK combined. Australian costs
are expected to be proportionate [3]. Furthermore,
based on the existing SCI UTI prevention literature,
we have demonstrated that current commonly used
methods of non-antibiotic UTI prevention in SCI do
not work [4]. The prevention of UTI, particularly the
more difficult to treat MRO UTI, is therefore a
clinical imperative for those people with SCI and
neurogenic bladder. Non-antibiotic prevention is needed
to prevent UTI without increasing the antimicrobial
resistance burden [5].
Probiotics are defined as a preparation containing
viable, defined micro-organisms in sufficient numbers,
which alter the microflora [by implantation or colonization]
in a compartment of the host and thus exert beneficial
health effects in this host [6]. Reid postulated that probio-
tics could reduce antibiotic related superinfections, disrupt
bacterial biofilms, and enhance generalised mucosal
immunity in the gastrointestinal and genitourinary
systems [7]. In a systematic review conducted by
Falagas et al., it was concluded that several probiotics
tested, e.g. Lactobacillus rhamnosus GR-1 and Lactobacil-
lus fermentum RC-14, delivered either intravaginally or
orally, were efficacious in restoring vaginal flora and in
preventing recurrent UTIs in women [8]. In another
trial, Manley et al. demonstrated clearance of vancomycin-
related enterococci in stool after treatment with Lactobacil-
lus rhamnosus GG [9].
There are currently no known trials of oral probiotics
and its efficacy in prevention of UTIs in people with
neurogenic bladders. Darouiche and others have con-
ducted more invasive trials involving inoculating neuro-
genic bladders with benign strains of Escherichia coli
and showed this approach was effective at lowering the
rate of UTIs per year [10–12].
Study aims
Primary aim
To test the effectiveness of combination oral probiotic
therapy Lactobacillus reuteri RC-14 + Lactobacillus
rhamnosus GR-1 [RC14-GR1 capsules] and/or Lacto-
bacillus rhamnosus GG + Bifidobacterium BB-12
[LGG-BB12 capsules] in preventing UTI in people
with SCI compared to placebo.
Secondary aims
a) To examine whether probiotics may change or
prevent colonisation or infection with MROs in
persons with SCI.
b) To examine the effects of probiotics on bowel
function in persons with SCI
c) Examination of indwelling and suprapubic catheters
to determine:
i) How probiotic intervention affects microbial
community composition in the urine and urinary
catheter.
ii) Differences between microbial communities in
individuals who are symptomatic versus
asymptomatic for UTI.
d) To estimate the cost-effectiveness of probiotics in
persons with SCI
A randomised controlled trial [RCT] was selected as
the design most likely to provide a definitive conclusion
to the primary aim.
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Methods/design
This is a prospective multi-site randomised, double-blind,
double-dummy, placebo-controlled factorial design trial
conducted in the state of New South Wales [NSW]
Australia, in order to test the effectiveness of two
probiotic therapies in preventing UTI in people with SCI.
Participants will be recruited from the NSW SCI commu-
nity and all the specialist SCI units in NSW hospitals,
including their regional and rural affiliations. These units
are located at the Prince of Wales Hospital [POWH],
Royal Rehabilitation Centre Sydney [RRCS] and Royal
North Shore Hospital [RNSH].
Ethics approval
A multi-site ethics approval was obtained from the
Human Research Ethics Committee [HREC] at each of
the three SCI units in NSW, Australia. HREC Protocol
no: 1008-282-CTN-GG [POWH SSA 1008-282 CTN,
RR SSA 11/SSA03, RNSH SSA10/HAWKE/171].
The protocol for catheter sampling and culture inde-
pendent technique of bacterial community identification
was categorised as a low-risk study with separate ethics
approval obtained from the HREC at each site [POWH
HREC ref no. 11/036, RNSH HREC/10/HARBR/102 and
SSA/10/HAWKE/171].
The trial was registered with the Australian New
Zealand Clinical Trials Registry [ACTRN 12610000512022]
on 21 June 2010. Informed consent will be provided prior
to recruitment and participation. Participant recruitment
commenced in April 2011.
Sample size
The trial uses a factorial design which allows the two
probiotics to be compared with placebo simultaneously
without inflating the sample size, on the assumption that
they do not interact with each other. [Refer Table 1].
UTI prevention: In our previous RCT with the same
study population [4], 45 % of participants had a symp-
tomatic UTI within six months. To have 80 % power
to detect [at 5 % two-sided significance level] a 30 %
reduction in the treatment group requires a total sam-
ple size of 350. Allowing for a 5 % loss to follow-up a
final sample size of 372 is required, 93 participants be-
ing randomly allocated to each of the four study
groups.
MRO treatment: It is expected that approximately 40 %
participants will be MRO-positive at enrolment. Assuming
5-10 % become MRO-negative in the control group, a
15–20 % reduction in MRO-positive colonisation rate
with probiotics would be detectable as significant at the
5 % level, with 80 % power, with a sample size of 372.
Randomisation and blinding of assessors
A simple stratified [computer generated] randomisation
protocol is used. JS is responsible for generating the allo-
cation sequence. Randomisation is stratified by bladder
management types [indwelling/suprapubic vs intermit-
tent catheters vs condom drainage/reflex voiding] as well
as inpatient/outpatient status. Randomisation occurs
following participant’s compliance check at Day 4. One
central pharmacy is responsible for the assignment and
distribution of the intervention for the entire study. All
four treatment regimens will be indistinguishable by
appearance and taste, and all participants receive the
same quantity of tablets. All clinical staff, researchers
and participants remain blind to treatment allocation
throughout this process. An audit of randomisation,
product allocation and dispensing stock will be performed
at the completion of the study by MT, who is not affiliated
with the final analysis and the clinical management of the
study or study participants.
Participants
All participants are to be over 18 years of age and are
required to provide written consent. All participants
with known neurogenic bladder as a result of SCI who
meet inclusion criteria and gave written consent are
enrolled. BL, ST, SR, JK, LB, GW and CBR are respon-
sible for enrolling participants.
Inclusion criteria:
1) Had a known neurogenic bladder;
2) Had a stable SCI or stable multiple sclerosis with a
known spinal demyelinating lesion;
3) Had a stable bladder management technique
[i.e. not receiving bladder management education
for at least 4 weeks] and using a bladder
management technique such as indwelling
catheter, suprapubic catheter, clean intermittent
self-catheterisation or reflex/condom drainage;
4) Agreed to fortnightly telephone consultation for
themselves and their care team during the six
month study period;
5) Agreed not to take any other probiotic in
addition to the allocated intervention during the
course of the study. This includes all oral or
topical preparations of yoghurt and urinary
antiseptics [e.g. methenamine hippurate
(hiprex) or cranberry preparations].







AB or Intervention A (93) Ab or Intervention B (93)
GR1-RC14 (a)
Placebo (186)
aB or Intervention C (93) ab or Intervention D (93)
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Exclusion criteria:
1. Receiving bladder management education within the
last 4 weeks;
2. Being treated for, or symptomatic from a current
infection or long-standing pressure sore;
3. Known to have a complex bladder disturbance
requiring surgical intervention e.g. known
cystoplasty, renal or bladder calculus, significant
hydronephrosis, or current pyelonephritis;
4. Known to have chronic open wound/s or known
long-standing osteomyelitis [greater than 6 weeks];
5. On long-term antibiotic therapy for any indication;
6. Known to have a history of adverse drug reaction to
yoghurt products or a demonstrated intolerance to
the probiotics used. Lactose intolerance was NOT an
exclusion criterion;
7. Known to have severe renal or hepatic failure;
8. Requiring full [invasive] mechanical ventilation;
9. Receiving immunosuppressant medications or
have an underlying immunosuppressive disease
[for example HIV or end-stage/ progressive
diabetes mellitus, multiple sclerosis or
cerebrovascular disease];
10.Planning to have oral surgery during the
intervention period;
11.Concurrently enrolled in another intervention study
[observational studies or inclusion following
completion of another study was allowed].
Each participant is enrolled for a six month study period,
which includes 24 weeks of treatment [see Fig. 1]. Each
participant randomised is required to take two tablets orally
each day consisting of either RC14-GR1 + LGG-BB12
Fig 1 Participant Study Flow Chart for ProSCIUTTU
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or RC14-GR1 + placebo or LGG-BB12 + placebo or 2
placebo tablets.
Active Interventions:
1. GR1-RC14. Concentration per capsule is 5.4 × 109
colony forming units.
2. LGG-BB12. Concentration per capsule is 7 × 109
colony forming units.
Participants will be assessed at Day 0, 3 months
and 6 months, supported by fortnightly phone calls
to determine health status and confirm intercurrent
symptomatic UTI status. [Fig. 1] Following witnessed
informed consent, evaluations conducted will be:
 Intervention issues and compliance.
 Quality of life assessment with the Short Form
Health Survey [SF-36] – baseline and 6 months plus
study endpoint if reached.
 Microbiological swabs of rectum, nose and groin,
urine culture and collection of urinary catheters for
participants with indwelling or suprapubic catheters
– baseline, 3 months and 6 months. Urine cultures
also performed if at study endpoint. Specific
instructions for sampling were given by study
co-ordinator to research assistants and community
nurses performing the swabs to ensure consistency.
 Bowel questionnaire [13, 14] - baseline and
3 months.
Catheter-bioflora analysis
The indwelling urethral and suprapubic catheter
biofilm is examined as a proxy for the urinary tract
microbial community. Culture-independent techniques
in profiling human microbes will be used to deter-
mine the composition of adherent microbes through
the examination of the bacterial 16S rDNA gene by
Terminal Restriction Fragment Length Polymorphism
[TRFLP] [15] and via next-generation sequencing
[16–19]
Samples are selected irrespective of interventional
grouping.
Samples are also selected from groups with re-
current symptomatic UTI compared to no-UTI symp-
toms over the study follow-up period. All TRFLP and
sequencing analysis will be conducted blinded by the
use of a participant identification key that de-identifies the
data.
TRFLP is done in collaboration with the Ramaciotti
Centre for Genomics, University of New South Wales
and sequencing through the Singapore Centre for En-
vironmental Life Sciences Engineering at Nanyang
Technological University, Singapore.
Study endpoints
1. The primary outcome measure is the time from
randomisation to occurrence of “symptomatic
UTI” [Fig. 2]. The date of the endpoint is the
date participants develop symptoms consistent
with a “symptomatic UTI” as per the algorithm,
not the date participants start developing any
symptoms. Table 2 outlines the definition of
“symptomatic UTI” as primary endpoint for
ProSCIUTTU. For participants who do not
experience a “symptomatic UTI”, the primary
outcome is at six months. Participants who cease
intervention early are followed up until the end of
the study period.
2. The secondary endpoint is time to change of
MRO colonisation status as determined by two
successive cultures [See guidelines for MRO
change or clearance in Additional file 1].
Data analysis
All analyses of outcomes will be by intention to treat,
apart from safety outcomes which will be according
to actual treatment received. Primary and MRO out-
comes will be analysed using survival analysis. Cox
regression modelling will be performed to test the
effect of each treatment while allowing for the other,
assuming no interaction effect. Hazard ratios and
Kaplan-Meier survival curves will be used to sum-
marise results. The extremely high prevalence of
MRO in SCI will also allow us to explore whether
probiotics can treat [or prevent] MRO colonisation in
this group.
A survey was sent out to selected co-authors for deter-
mining the strength of association of several variables in
regards to UTI in the SCI population [pre hoc review].
Only variables which have strong or moderate associ-
ation will be included in the analysis.
Biofilms will be analysed using a combination of RNA
based meta-community sequencing, TRFLP fingerprinting
and culture based methods.
Trial data management
The data will be collected on trial specific case record
forms. OM is responsible for designing and maintaining
the trial database. Following each study visit, a study
team member will ensure data is complete. Databases
will be commissioned within the SCI units and will
contain non-identifiable data. Re-identifiable data will be
available for use only by the study team. Primary
outcome measure endpoint determination will be veri-
fied by BL and ST. The two assessors will be blinded by
each other’s assessment. Discrepancies will be decided
by a third investigator [KC].
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Feasability, safety, efficacy
Efficacy
The primary study endpoint is symptomatic UTI with
microbiological evidence of infection [refer to Fig. 2 and
Table 2]. However, other secondary measures of interest
include:
 Clinical infection.
 Hospital admissions and intensive care unit
admissions related to infection.
 A diagnosis of laboratory infection defined by a
positive blood culture.
 Clinical adverse events [grade 3–4] regardless of
causality.
 All causes of mortality.
 Use of antibiotics.
 Change in of MRO colonisation/infection status as
defined by two consecutive MRO swabs three
months apart.
 Modifications of bladder management.
 SF-36
 A cost-effectiveness analysis will be undertaken
using SF-6D utility weights derived from the
SF-36. In addition to antibiotic use, the following
Fig 2 Definition of primary endpoint UTI for ProSCIUTTU (need to refer to Table 2)
Lee et al. BMC Urology  (2016) 16:18 Page 6 of 8
resource data will also be collected during the
study:




– Infection control auditing
Safety monitoring
An independent Safety Monitoring Committee [SMC] is
established. Clinicians or investigators responsible for
the clinical care of study participants were not permitted
to be members of the SMC. The SMC will monitor the
trial and review safety data by treatment allocation.
Safety monitoring will be carried out at various intervals
through the trial depending on frequency of adverse
events. The Committee will review laboratory data, Grade
3, Grade 4 and Grade 5 adverse events and serious adverse
events [SAEs] and adverse events leading to cessation of
study therapy [refer Table 3]. A summary of safety data
will be undertaken when all recruited participants have
completed 20 weeks on study.
The SMC Chairman had no formal affiliation with the
trial and coordinated this process.
Project governance and administration support
The chief investigator Dr. Bon San Bonne Lee will be re-
sponsible for overall project management, but is assisted
and advised by a project steering committee comprised of
the collaborating researchers and administrative support
from the administering institution [NeuRA]. The project
steering committee will meet regularly and all agendas
and minutes circulated to all stakeholders.
Table 2 Definition of "symptomatic UTI" as primary endpoint for ProSCIUTTU (need to refer to Fig. 2). Use the following table to
assess “Category 1”, or Two “Category 2” and any “Category 3” Symptoms: All symptoms should be asked in each category
“Category 1” Symptoms:* “Category 2” Symptoms:* “Category 3” Symptoms:
Two or more In themselves not enough to lead
to treatment but recorded for
International Spinal Cord Injury Urinary
Tract Infection Datasets Compatibility
• Temperature:Greater than 38 ° C core
Greater than 37.5 ° C per axilla
• New or increasing symptoms of
Autonomic Dysreflexia, as detected by
any of the following signs: Pulse < 50
or increased flushing or sweating or
headache AND increased B.P Diastolic
or Systolic > 25 % usual baseline.
• Increased Frequency of Muscle Spasms or spasticity
• Failure of usual control of urinary incontinence-any
of the following constitutes fulfillment of this
category-Bladder Spasm-Urinary frequency or
need for increased catheterization-Urinary
Retention-Urinary Urgency-Leaking around
catheter site or per urethra if have
suprapubic catheter
• New Scrotal/Loin/Abdominal Discomfort
unexplained by other pathology - any of
the following constitutes fulfillment of this
category-Abdominal Pain-Bladder/Suprapubic
Pain-Loin/Back Pain-Scrotal Pain-Dysuria




Urine-Foul smelling urine-Blood in urine
haematuria-Catheter blockage
*Content adapted and modified from Box 1 of Spinal-injured neuropathic bladder antisepsis (SINBA) trial [4]
Table 3 Severity grade of adverse events
ESTIMATING SEVERITY GRADE
PARAMETER GRADE 1 GRADE 2 GRADE 3 GRADE 4









to perform usual social
& functional activities
Symptoms causing inability to
perform basic self-care functions
OR Medical or operative intervention
indicated to prevent permanent
impairment, persistent disability
Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue intervention at the discretion of the investigator
Grade 3 Laboratory Abnormality or Clinical Event
Grade 3 clinically significant laboratory abnormalities should be confirmed by repeat testing within three to five calendar days of receipt of results and before
discontinuation, unless such a delay is not consistent with good medical practice
For grade 3 clinical events, continue if the event is considered to be unrelated to the intervention. For a grade 3 clinical event, or clinically significant laboratory
abnormality confirmed by repeat testing, that is considered to be related to the intervention, both oral and bodywash interventions should be withheld until the
toxicity returns to ≤ grade 2. When restarting following resolution of the adverse event, both interventions to be restarted simultaneously following discussion
with the study monitor
Grade 4 Laboratory Abnormality or Clinical Event For grade 4 clinical event or clinically significant laboratory abnormality confirmed by repeat testing that is
considered related to the intervention, the intervention should be permanently discontinued and subjects managed according to local practice. The subject
should be followed as clinically indicated until the event resolves to baseline, or is otherwise explained, whichever occurs first. Study interventions may be
continued without modification for non-clinically significant grade 4 laboratory abnormality (e.g. triglyceride elevation that is non-fasting or that can be medically
managed) or clinical event considered unrelated to the study intervention
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Trial status
Trial commencement date: April 2011
Trial follow-up completion date: March 2014
Number of participants recruited: 207
Additional file
Additional file 1: Guidelines for MRO change and clearance. (DOC 27 kb)
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